from maternal serum. Referring to this, Legler et al. [5] present a timely review of current European efforts. Cost-effective screening for donors with rare antigen profiles represents another up-to-date topic and is picked out twice as a central one in this issue by Jungbauer [6] and Wagner [7] . Since nobody can do without quality control nowadays, an example of how molecular blood group diagnostics might influence serological validation processes is presented by Gassner et al. [8] . No matter which method is being used and blood group polymorphisms are being analysed, there will always be a certain percentage of samples remaining inconclusive when combining serological and molecular biological results. In most cases, these results will present new blood group alleles, and there is a vital interest for resolving these cases by means of DNA sequence-based typing as being detailed by Seltsam and Doescher [9] .
Five expert opinions on the question 'Will genotyping replace serology routine blood grouping in the future?' represent a third key aspect of this issue [10] [11] [12] [13] [14] . Experts are being challenged by giving editorial sub-queries such as: 'Should there be genotyping for 'all' (currently available) blood groups of all donors? Could there be additional testing for genetic markers encoding 'soft' genetic diseases such as e.g. haemochromatosis, hereby extending responsibility range of blood typing centres in the context of public health? Could there be a blood group serologists' approval for 'in silico' cross-matching, given all available blood groups of each transfusion event were genetically determined?'
Browsing the content of this issue, most of the technical applications which are being presented are developed and tested in highly specialised laboratories only. Some of them will always remain there. Others will might be picked up by the industry and made accessible to the end users. In any case, skilled experts in molecular biology and intense cross-talk to medical specialists are two irreplaceable prerequisites for an innovative application of modern molecular blood group diagnostics.
Molecular Blood Group Diagnostics 155
